Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: Promise and concern
- 1 August 2009
- journal article
- editorial
- Published by Elsevier in Journal of American Association for Pediatric Ophthalmology and Strabismus
- Vol. 13 (4) , 329-331
- https://doi.org/10.1016/j.jaapos.2009.06.003
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Pharmacokinetics of Bevacizumab after Topical, Subconjunctival, and Intravitreal Administration in RabbitsInvestigative Opthalmology & Visual Science, 2009
- Antivascular endothelial growth factor therapy for neovascular age-related macular degenerationCurrent Opinion in Opthalmology, 2009
- Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degenerationCurrent Opinion in Opthalmology, 2009
- THE EFFECT OF UNILATERAL INTRAVITREAL BEVACIZUMAB (AVASTIN), IN THE TREATMENT OF DIFFUSE BILATERAL DIABETIC MACULAR EDEMARetina, 2009
- Bilateral improvement of persistent diffuse diabetic macular oedema after unilateral intravitreal bevacizumab (Avastin) injectionEye, 2008
- Annual Rates of Arterial Thromboembolic Events in Medicare Neovascular Age-Related Macular Degeneration PatientsOphthalmology, 2007
- Intravitreal Ranibizumab and Bevacizumab: A Review of RiskSeminars in Ophthalmology, 2007
- Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic RetinopathyPublished by Elsevier ,2006
- Ranibizumab: treatment in patients with neovascular age-related macular degenerationExpert Opinion on Biological Therapy, 2006
- Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal AdministrationInvestigative Opthalmology & Visual Science, 2005